Correspondence 0001213900-24-071209 from Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Date: Aug. 20, 2024 · CIK: 0001708331 · Accession: 0001213900-24-071209
AI Filing Summary & Sentiment
File numbers found in text: 333-281080
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Doris Gama Re: Virpax Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed July 29, 2024 File No: 333-281080
Dear Ms. Gama:
Virpax Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as amended (File No. 333-281080), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective today, Thursday, August 22, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow and/or Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238, or Ms. Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours,
VIRPAX PHARMACEUITCALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
August 20, 2024
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Doris Gama
Re:
Virpax Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed July 29, 2024
File No: 333-281080
Dear Ms. Gama:
Virpax Pharmaceuticals, Inc. (the
“Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as
amended (File No. 333-281080), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to
become effective today, Thursday, August 22, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands
that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities
under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes
Leslie Marlow and/or Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact
Ms. Marlow at (516) 457-4238, or Ms. Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify
either of them when this request for acceleration has been granted.
Very truly yours,
VIRPAX PHARMACEUITCALS, INC.
By:
/s/ Gerald Bruce
Name:
Gerald Bruce
Title:
Chief Executive Officer
cc:
Leslie Marlow, Blank Rome LLP
Melissa Palat Murawsky, Blank Rome LLP